| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
| Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00000809 |
Purpose
The purpose of this study is to test the safety and effectiveness of two different formulations of an HIV vaccine in infants born to HIV-infected women.
| Condition | Intervention | Phase |
|
HIV Infections HIV Seronegativity |
Biological: Aluminum hydroxide Biological: QS-21 Biological: MN rsgp120/HIV-1 |
Phase I |
| MedlinePlus related topics: | AIDS |
| Drug Information available for: | Aluminum hydroxide Algeldrate QS 21 Aluminum Aluminum sulfate |
| Study Type: | Interventional |
| Study Design: | Prevention, Dose Comparison |
| Official Title: | A Phase I Trial of the Safety and Immunogenicity of MN rsgp120/HIV-1 With the Adjuvants QS-21 and Alum Compared to MN rsgp120/HIV-1 and QS-21 in Infants Born to HIV-Infected Women |
Eligibility
| Ages Eligible for Study: | up to 3 Days |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria
Infants may be eligible for this study if they:
Contacts and Locations More Information
| Study ID Numbers: | ACTG 279 |
| First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000809 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|
|
